Revenue
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2023
2024
2025
Xenon Pharmaceuticals Inc. (XENE)
Price$58.65Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $0 | $0 | $9.4M | $18.4M | $32.2M | $6.8M | — | $311,000 | $1.8M | $15.6M | $28.4M | $27.4M | $14.3M |
| Research & development | $300.9M | $210.4M | $167.5M | $105.8M | $75.5M | $50.5M | $38.8M | $23.6M | $25.6M | $19.8M | $15.2M | $11.8M | $12.3M | $10.5M |
| Operating expenses | $380.6M | $279.3M | $214.1M | $138.6M | $97.4M | $63.5M | $49.6M | $38.0M | $32.9M | $26.6M | $24.9M | $17.3M | $17.6M | $17.5M |
| Operating income | −$373.1M | −$279.3M | −$214.1M | −$129.1M | −$79.0M | −$31.3M | −$42.8M | −$38.0M | −$32.6M | −$24.8M | −$9.4M | $11.1M | $9.7M | −$3.2M |
| Operating margin | −4,974.27% | — | — | −1,368.91% | −428.45% | −97.31% | −627.02% | — | −10,474.28% | −1,376.43% | −60.10% | 39.15% | 35.50% | −22.04% |
| EBITDA | −$370.5M | −$276.7M | −$212.0M | −$127.7M | −$78.1M | −$30.7M | −$42.4M | −$37.5M | −$31.9M | −$24.0M | −$8.3M | $11.8M | $10.4M | −$2.4M |
| EBITDA margin | −4,940.36% | — | — | −1,354.02% | −423.53% | −95.31% | −620.74% | — | −10,265.59% | −1,328.51% | −53.43% | 41.75% | 38.08% | −16.54% |
| Net income | −$345.9M | −$234.3M | −$182.4M | −$125.4M | −$78.9M | −$28.8M | −$41.6M | −$34.5M | −$30.7M | −$23.0M | −$15.8M | $13.0M | $12.0M | −$4.3M |
| Net profit margin | −4,612.13% | — | — | −1,328.95% | −427.85% | −89.65% | −609.09% | — | −9,872.67% | −1,275.49% | −101.12% | 45.89% | 43.98% | −30.06% |
| Basic EPSper basic share | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | -$1.54 | -$1.63 | -$1.71 | -$1.48 | -$1.10 | $4.11 | $2.87 | -$3.24 |
| Diluted EPSper diluted share | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 | -$1.54 | -$1.63 | -$1.72 | -$1.48 | -$1.10 | $3.28 | $1.91 | -$3.24 |
Owners
Reported shareholders
9.97%of listed shares
FMR LLC9.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 9.97%9.65M shares |
BlackRock, Inc. | 7.77%7.52M shares |
Avoro Capital Advisors LLC | 5.97%5.78M shares |
Polar Capital Holdings Plc | 4.72%4.57M shares |
Driehaus Capital Management LLC | 4.57%4.42M shares |
Jupiter Topco LLC | 4.33%4.19M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.36%3.25M shares |
JPMORGAN CHASE & CO | 2.71%2.62M shares |
Capital International Investors | 2.44%2.36M shares |
T. Rowe Price Investment Management, Inc. | 2.24%2.17M shares |
STATE STREET CORP | 2.04%1.97M shares |
TWO SIGMA INVESTMENTS, LP | 1.70%1.64M shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 1.67%1.62M shares |
Affinity Asset Advisors, LLC | 1.65%1.6M shares |
ALLIANCEBERNSTEIN L.P. | 1.61%1.56M shares |
WESTFIELD CAPITAL MANAGEMENT CO LP | 1.56%1.51M shares |
FRANKLIN RESOURCES INC | 1.49%1.44M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.47%1.43M shares |
CITADEL ADVISORS LLC | 1.45%1.4M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.42%1.37M shares |
Percentages use 96.75M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2026Form 4 · 10b5-1 | PATOU GARYDirector | SellCommon Shares | 1.3K | $53.14 | $70.3K | 24.9K |
| Jun 5, 2026Form 4 · 10b5-1 | Cannon GillianDirector | SellCommon Shares | 1.2K | $53.14 | $63.2K | 1.5K |
| Mar 13, 2026Form 4 · 10b5-1 | KENNEY CHRISTOPHER JOHNChief Medical Officer | SellCommon Shares | 1.4K | $55.23 | $77.9K | 7.1K |
| Mar 13, 2026Form 4 · 10b5-1 | DiFabio AndreaChief Legal Officer | SellCommon Shares | 1.3K | $55.23 | $74.1K | 7.3K |
| Mar 13, 2026Form 4 · 10b5-1 | MORTIMER IANPRESIDENT & CEO | SellCommon Shares | 7.3K | $55.23 | $403.6K | 19.9K |
Community posts
Xenon files its seizure-drug application while pausing new psychiatry enrollment
Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation t ...
